focus -WSS

focus

author：explore 2025-09-27 09:46:28 - browse：3461

Alnylam headquarters — Kristoffer Tripplaar/Sipa USA/AP

The Food and Drug Administration rejected an Alnylam Pharmaceuticals’ therapy for an increasingly prevalent heart disease, the company said Monday, citing insufficient evidence that the treatment meaningfully improved patients’ lives.

Alnylam will no longer seek approval of its drug, an intravenous medicine sold as Onpattro, for people with ATTR-CM, a progressive disease that leads to heart failure if left untreated. The company is in the late stages of development of an updated version of Onpattro that can be administered through a small needle under the skin. Data from a pivotal study, expected next year, would support an FDA application for that treatment.

For Onpattro, a 12-month clinical trial found that the treatment outperformed placebo on a test of how far patients could walk over the course of six minutes, suggesting the medicine slowed down the progression of ATTR-CM. Onpattro also improved patients’ scores on a quality-of-life questionnaire compared to placebo.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： Seth Rogen and Lauren Miller Rogen on Alzheimer's caregiving

focus

WSS

Seth Rogen and Lauren Miller Rogen on Alzheimer's caregiving

Amazon on where the company's health care bets are headed next

Mark Cuban is blaming the wrong people for high drug costs

How to fix cancer clinical trials' diversity problem

Weighted lottery helped low

After Optum profits sink, UnitedHealth makes changes

Wikipedia

focus

leisure time

Apple is now the first public company to be valued at $3 trillion

Ethical issues complicate the benefits of medical crowdfunding

Alkermes shareholders re

The 10 drugs up first for Medicare price negotiation

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Advances in CAR

Duchenne breakthrough therapy leaves behind pioneering families

Biotech execs pursue obesity drug boom: ‘It’s the early innings’

Heart attack and stroke risk calculators need revising

Be careful with at

focus

Maui wildfire now ranks as the fifth

Novo Nordisk touts Wegovy study, but still struggling with supply

Surge in Apellis stock fueled by confidence in safety of its eye drug

Stem cell treatment guidelines are released by FDA

YouTube cracks down on misinformation on cancer treatment

Patients, digital health players weigh in on FTC's data privacy plan

focus

hotspot

hotspot

hotspot